Home > Dermatology > EADV 2019 > Emerging Therapies > IL-4/IL-13 blockade leads to rapid itch reduction in adolescents

IL-4/IL-13 blockade leads to rapid itch reduction in adolescents

Expert
Prof. Eric Simpson, Oregon Health & Science University, USA
Conference
EADV 2019
Trial
Phase 3, LIBERTY AD ADOL

A post-hoc analysis of the phase 3 trial LIBERTY AD ADOL showed that dupilumab entails a rapid itch reduction after only 5 days in adolescents with moderate-to-severe atopic dermatitis (AD) [1].

Itch is the moth bothersome symptom for patients with AD most and it is furthermore associated with sleep loss, reduced quality of life, and reduced productivity. “With our analysis, we wanted to find out how long it will take to relieve itch. This is especially interesting in comparison with JAK inhibitors,” said Prof. Eric Simpson (Oregon Health & Science University, USA). The LIBERTY AD ADOL trial included 251 adolescent patients (aged 12 to 18 years). They were randomised to subcutaneous dupilumab every 2 weeks in 2 dosages according to body weight (< 60 kg or ≥ 60 kg), dupilumab every 4 weeks, or placebo over 16 weeks. The co-primary endpoints of the study were: percentage of participants wit...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on